BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9869396)

  • 1. Stromal expression of urokinase-type plasminogen activator receptor (uPAR) is associated with invasive growth in primary liver cancer.
    Akahane T; Ishii M; Ohtani H; Nagura H; Toyota T
    Liver; 1998 Dec; 18(6):414-9. PubMed ID: 9869396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma.
    Dubuisson L; Monvoisin A; Nielsen BS; Le Bail B; Bioulac-Sage P; Rosenbaum J
    J Pathol; 2000 Feb; 190(2):190-5. PubMed ID: 10657018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas.
    Somorácz A; Tátrai P; Horváth G; Kiss A; Kupcsulik P; Kovalszky I; Schaff Z
    Hum Pathol; 2010 Sep; 41(9):1310-9. PubMed ID: 20471664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma.
    Morita Y; Hayashi Y; Wang Y; Kanamaru T; Suzuki S; Kawasaki K; Ohta K; Yamamoto M; Saitoh Y; Itoh H; Doe WF
    Hepatology; 1997 Apr; 25(4):856-61. PubMed ID: 9096588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
    Zhou Q; Liang LJ; Peng BG; Zhen YY
    Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase type plasminogen activator receptor expression in colorectal neoplasms.
    Suzuki S; Hayashi Y; Wang Y; Nakamura T; Morita Y; Kawasaki K; Ohta K; Aoyama N; Kim SR; Itoh H; Kuroda Y; Doe WF
    Gut; 1998 Dec; 43(6):798-805. PubMed ID: 9824607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets.
    Kaemmerer D; Schindler R; Mußbach F; Dahmen U; Altendorf-Hofmann A; Dirsch O; Sänger J; Schulz S; Lupp A
    BMC Cancer; 2017 Dec; 17(1):896. PubMed ID: 29282035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas.
    Nakatsukasa H; Ashida K; Higashi T; Ohguchi S; Tsuboi S; Hino N; Nouso K; Urabe Y; Kinugasa N; Yoshida K; Uematsu S; Ishizaki M; Kobayashi Y; Tsuji T
    Hepatology; 1996 Jul; 24(1):82-8. PubMed ID: 8707287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
    Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
    Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis.
    Kim H; Choi GH; Na DC; Ahn EY; Kim GI; Lee JE; Cho JY; Yoo JE; Choi JS; Park YN
    Hepatology; 2011 Nov; 54(5):1707-17. PubMed ID: 22045674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
    Buø L; Meling GI; Karlsrud TS; Johansen HT; Aasen AO
    Hum Pathol; 1995 Oct; 26(10):1133-8. PubMed ID: 7557947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
    Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
    J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'.
    Kozaka K; Sasaki M; Fujii T; Harada K; Zen Y; Sato Y; Sawada S; Minato H; Matsui O; Nakanuma Y
    Histopathology; 2007 Sep; 51(3):390-400. PubMed ID: 17553067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differing expression of MMPs-1 and -9 and urokinase receptor between diffuse- and intestinal-type gastric carcinoma.
    Migita T; Sato E; Saito K; Mizoi T; Shiiba K; Matsuno S; Nagura H; Ohtani H
    Int J Cancer; 1999 Feb; 84(1):74-9. PubMed ID: 9988236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
    De Petro G; Tavian D; Copeta A; Portolani N; Giulini SM; Barlati S
    Cancer Res; 1998 May; 58(10):2234-9. PubMed ID: 9605771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
    Duggan C; Maguire T; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
    Int J Cancer; 1995 May; 61(5):597-600. PubMed ID: 7768629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
    Zimmerman RL; Fogt F; Burke M; Murakata LA
    Oncol Rep; 2002; 9(4):689-92. PubMed ID: 12066193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.